Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-&amp;beta; fibrils

Skaat, Hadas; Corem-Slakmon, Enav; Grinberg, Igor; Goez, David; Mardor, Yael; Margel, Shlomo

doi:10.2147/ijn.s52833

Cited by 14 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pioneering work of Poduslo et al [ 199 ] and in a number of later studies, β-amyloid peptides or their fragments and derivatives were conjugated with gadolinium complexes [ 200 , 201 , 202 ] or superparamagnetic iron oxide nanoparticles (SPIONs) [ 203 , 204 ]. Alternatively, β-amyloid antibodies and their derivatives or fragments were conjugated [ 205 , 206 , 207 , 208 , 209 ]. Many recent studies have employed Gd 3+ chelates or iron oxide nanoparticles covalently or noncovalently linked with organic ligands binding Aβ fibrils.…”

Section: Molecular Design Of Mri Fibril-binding Probesmentioning

confidence: 99%

Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits

Nikiforova

Sedov

2023

IJMS

View full text Add to dashboard Cite

The ability to detect and monitor amyloid deposition in the brain using non-invasive imaging techniques provides valuable insights into the early diagnosis and progression of Alzheimer’s disease and helps to evaluate the efficacy of potential treatments. Magnetic resonance imaging (MRI) is a widely available technique offering high-spatial-resolution imaging. It can be used to visualize amyloid deposits with the help of amyloid-binding diagnostic agents injected into the body. In recent years, a number of amyloid-targeted MRI probes have been developed, but none of them has entered clinical practice. We review the advances in the field and deduce the requirements for the molecular structure and properties of a diagnostic probe candidate. These requirements make up the base for the rational design of MRI-active small molecules targeting amyloid deposits. Particular attention is paid to the novel cryo-EM structures of the fibril aggregates and their complexes, with known binders offering the possibility to use computational structure-based design methods. With continued research and development, MRI probes may revolutionize the diagnosis and treatment of neurodegenerative diseases, ultimately improving the lives of millions of people worldwide.

show abstract

Section: Molecular Design Of Mri Fibril-binding Probesmentioning

confidence: 99%

Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits

Nikiforova

Sedov

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, the positively charged SPIONs promoted fibrillation at significantly lower particle concentrations. In addition, peptide- and antibody-modified MNPs also significantly inhibited Aβ fibrillation [ 105 , 106 ].…”

Section: Nanomaterialsmentioning

confidence: 99%

Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides

et al. 2021

View full text Add to dashboard Cite

The aberrant aggregation of amyloid-β (Aβ) peptides in the brain has been recognized as the major hallmark of Alzheimer’s disease (AD). Thus, the inhibition and dissociation of Aβ aggregation are believed to be effective therapeutic strategiesforthe prevention and treatment of AD. When integrated with traditional agents and biomolecules, nanomaterials can overcome their intrinsic shortcomings and boost their efficiency via synergistic effects. This article provides an overview of recent efforts to utilize nanomaterials with superior properties to propose effective platforms for AD treatment. The underlying mechanismsthat are involved in modulating Aβ aggregation are discussed. The summary of nanomaterials-based modulation of Aβ aggregation may help researchers to understand the critical roles in therapeutic agents and provide new insight into the exploration of more promising anti-amyloid agents and tactics in AD theranostics.

show abstract

“…By applying the immunomagnetic reduction (IMR) assay, the concentration can be detected, which is lower than 10 pg/ml at Aβ-40 and 20 pg/ml at Aβ-42 and, furthermore, with high specificity (Yang et al, 2011a). Skaat et al (2013) reported that the fixation of the aAβmAb clone BAM10 to near-infrared fluorescent maghemite nanoparticles enables to detect Aβ 40 fibrils specifically ex vivo by both fluorescence and MRI.…”

Section: Iron Oxide Nanoparticles In the Diagnosis Of Ad In Vitromentioning

confidence: 99%

Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

Luo

Zhu

et al. 2020

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils

Cited by 14 publications

References 55 publications

Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits

Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits

Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides

Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

Contact Info

Product

Resources

About